FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307431144> ?p ?o ?g. }

• W4307431144 endingPage "2690" @default.
• W4307431144 startingPage "2679" @default.
• W4307431144 abstract "Abstract Daratumumab monotherapy demonstrated favorable safety and efficacy in relapsed/refractory multiple myeloma (RRMM) patients in the global phase 1/2 GEN501 and phase 2 SIRIUS studies. MMY1003 evaluated daratumumab monotherapy specifically in Chinese patients with RRMM. This 3-part, open-label, phase 1, dose-escalation study included patients with ≥ 2 prior lines of therapy. Part 3 included patients who had received a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) and experienced disease progression on their last regimen. Patients received intravenous daratumumab 8 mg/kg or 16 mg/kg in part 1 and 16 mg/kg in parts 2 + 3. Primary endpoints were dose-limiting toxicity (DLT; part 1), pharmacokinetics (parts 1 + 2), and adverse events (AEs). Fifty patients enrolled. The first 3 patients in part 1 received daratumumab 8 mg/kg; remaining patients in parts 1–3 received daratumumab 16 mg/kg. In the daratumumab 16 mg/kg group ( n = 47), patients received a median of 4 prior lines of therapy; 32% were refractory to a PI and IMiD, and 79% were refractory to their last prior therapy. No DLTs occurred. Thirty-six (77%) patients reported grade 3/4 treatment-emergent AEs. Thirteen (28%) patients experienced infusion-related reactions. At an 18.5-month median follow-up, overall response rate was 43%. Median progression-free survival (PFS) and overall survival (OS) were 6.7 months and not reached, respectively; 12-month PFS and OS rates were 35% and 70%. Pharmacokinetic results ( n = 22) were consistent with other studies. Safety, pharmacokinetics, and efficacy of daratumumab monotherapy were confirmed in Chinese patients with RRMM. This trial is registered on ClinicalTrials.gov (NCT02852837)." @default.
• W4307431144 created "2022-11-01" @default.
• W4307431144 creator A5000239300 @default.
• W4307431144 creator A5010388094 @default.
• W4307431144 creator A5017804632 @default.
• W4307431144 creator A5042515616 @default.
• W4307431144 creator A5044422446 @default.
• W4307431144 creator A5044433615 @default.
• W4307431144 creator A5048988662 @default.
• W4307431144 creator A5051994266 @default.
• W4307431144 creator A5056736359 @default.
• W4307431144 creator A5067469709 @default.
• W4307431144 creator A5070038280 @default.
• W4307431144 creator A5089404504 @default.
• W4307431144 creator A5089850088 @default.
• W4307431144 date "2022-10-27" @default.
• W4307431144 modified "2023-10-01" @default.
• W4307431144 title "Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)" @default.
• W4307431144 cites W1585625390 @default.
• W4307431144 cites W1902692042 @default.
• W4307431144 cites W2003734726 @default.
• W4307431144 cites W2044436186 @default.
• W4307431144 cites W2066800926 @default.
• W4307431144 cites W2140579395 @default.
• W4307431144 cites W2141502099 @default.
• W4307431144 cites W2158608759 @default.
• W4307431144 cites W2229483068 @default.
• W4307431144 cites W2400276917 @default.
• W4307431144 cites W2402003835 @default.
• W4307431144 cites W2443548094 @default.
• W4307431144 cites W2494994085 @default.
• W4307431144 cites W2512106959 @default.
• W4307431144 cites W2528329272 @default.
• W4307431144 cites W2551291014 @default.
• W4307431144 cites W2553693801 @default.
• W4307431144 cites W2557319359 @default.
• W4307431144 cites W2763640819 @default.
• W4307431144 cites W2905082484 @default.
• W4307431144 cites W3001644080 @default.
• W4307431144 cites W3032537564 @default.
• W4307431144 cites W3032742617 @default.
• W4307431144 cites W3097653069 @default.
• W4307431144 doi "https://doi.org/10.1007/s00277-022-04951-3" @default.
• W4307431144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36301338" @default.
• W4307431144 hasPublicationYear "2022" @default.
• W4307431144 type Work @default.
• W4307431144 citedByCount "1" @default.
• W4307431144 countsByYear W43074311442023 @default.
• W4307431144 crossrefType "journal-article" @default.
• W4307431144 hasAuthorship W4307431144A5000239300 @default.
• W4307431144 hasAuthorship W4307431144A5010388094 @default.
• W4307431144 hasAuthorship W4307431144A5017804632 @default.
• W4307431144 hasAuthorship W4307431144A5042515616 @default.
• W4307431144 hasAuthorship W4307431144A5044422446 @default.
• W4307431144 hasAuthorship W4307431144A5044433615 @default.
• W4307431144 hasAuthorship W4307431144A5048988662 @default.
• W4307431144 hasAuthorship W4307431144A5051994266 @default.
• W4307431144 hasAuthorship W4307431144A5056736359 @default.
• W4307431144 hasAuthorship W4307431144A5067469709 @default.
• W4307431144 hasAuthorship W4307431144A5070038280 @default.
• W4307431144 hasAuthorship W4307431144A5089404504 @default.
• W4307431144 hasAuthorship W4307431144A5089850088 @default.
• W4307431144 hasBestOaLocation W43074311441 @default.
• W4307431144 hasConcept C112705442 @default.
• W4307431144 hasConcept C121332964 @default.
• W4307431144 hasConcept C126322002 @default.
• W4307431144 hasConcept C141071460 @default.
• W4307431144 hasConcept C142424586 @default.
• W4307431144 hasConcept C143998085 @default.
• W4307431144 hasConcept C197934379 @default.
• W4307431144 hasConcept C2776063141 @default.
• W4307431144 hasConcept C2776364478 @default.
• W4307431144 hasConcept C2776694085 @default.
• W4307431144 hasConcept C2780739268 @default.
• W4307431144 hasConcept C2781119759 @default.
• W4307431144 hasConcept C2781413609 @default.
• W4307431144 hasConcept C29730261 @default.
• W4307431144 hasConcept C31760486 @default.
• W4307431144 hasConcept C71924100 @default.
• W4307431144 hasConcept C87355193 @default.
• W4307431144 hasConcept C90924648 @default.
• W4307431144 hasConceptScore W4307431144C112705442 @default.
• W4307431144 hasConceptScore W4307431144C121332964 @default.
• W4307431144 hasConceptScore W4307431144C126322002 @default.
• W4307431144 hasConceptScore W4307431144C141071460 @default.
• W4307431144 hasConceptScore W4307431144C142424586 @default.
• W4307431144 hasConceptScore W4307431144C143998085 @default.
• W4307431144 hasConceptScore W4307431144C197934379 @default.
• W4307431144 hasConceptScore W4307431144C2776063141 @default.
• W4307431144 hasConceptScore W4307431144C2776364478 @default.
• W4307431144 hasConceptScore W4307431144C2776694085 @default.
• W4307431144 hasConceptScore W4307431144C2780739268 @default.
• W4307431144 hasConceptScore W4307431144C2781119759 @default.
• W4307431144 hasConceptScore W4307431144C2781413609 @default.
• W4307431144 hasConceptScore W4307431144C29730261 @default.
• W4307431144 hasConceptScore W4307431144C31760486 @default.
• W4307431144 hasConceptScore W4307431144C71924100 @default.
• W4307431144 hasConceptScore W4307431144C87355193 @default.

• next